Dyne Therapeutics Inc (DYN) Quarterly Institutional 13F Update (Q2 2026)

DYN ranks #2497 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

DYN is a top-conviction position for Atlas Venture Life Science Advisors, LLC — at 17.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in DYN belongs to T. Rowe Price Investment Management, Inc., but the position matters far more to Atlas Venture Life Science Advisors, LLC, who has 17.1% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

T. Rowe Price has added to its DYN position for two straight quarters, increasing it by $343.5M to reach $686.6M today.

Adage Capital Partners Gp, L.l.c. has trimmed its DYN position for two straight quarters, cutting it by $97.8M while still holding $3.3M.

DYN is up 0.2% today, and institutions have been net buyers of $224.4M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

DYN reported a net loss of $446.2M in its latest fiscal year.

• Not yet profitable — net loss of $446.2M in the latest fiscal year
• Net income declined year over year, from -$317.4M to -$446.2M
• Operating cash flow was negative, using $403.2M in cash
• Current ratio of 22.25x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.22x equity — within a conventional range